Core Viewpoint - Shenzhen Haijing Zhiyuan Technology Co., Ltd. has transformed from a loss of millions to a successful applicant for the main board listing on the Hong Kong Stock Exchange, submitting its application again on March 16 after the first attempt failed [1]. Group 1: Company Overview - Haijing Zhiyuan aims to leverage capital to expand its applications in emerging scenarios such as Internet Data Center (IDC) security, industrial commercial security, and Internet of Things (IoT) facility management [2]. - The company has developed a technological moat through its ability to acquire and process multispectral information, including visible light, infrared, and ultraviolet [3]. - The company has been recognized as a national-level "specialized and innovative" small giant enterprise in 2022 and further acknowledged as a key "small giant" enterprise in 2025, holding 98 invention patents and 46 software copyrights [4]. Group 2: Financial Performance - For the fiscal year 2023, the company reported revenues of RMB 117.063 million, with projected revenues of RMB 522.568 million for 2024 and RMB 668.519 million for 2025 [3]. - The cost of sales for 2023 was RMB (102.756) million, with projections of RMB (424.399) million for 2024 and RMB (519.127) million for 2025 [3]. - The operating loss for 2023 was RMB (20.412) million, but it is projected to turn into an operating profit of RMB 43.202 million in 2024 and RMB 31.146 million in 2025 [3].

Group 1: IPO Overview - This week, three companies submitted their IPO applications: Junsheng Electronics, Haijing Zhiyuan, and Haixi New Drug [2][3] - Next week, Yinnuo Pharmaceutical-B (weight loss drug) and Zhonghui Biotechnology-B (vaccine) are expected to be listed, presenting potential investment opportunities [1][2] Group 2: Company Profiles - **Junsheng Electronics**: A leading provider of smart automotive technology solutions, ranked 41st globally in the automotive parts industry in 2024. The company is the second-largest supplier of passive safety products in China and globally, with 74.7% of its revenue from overseas sales in 2024 [3] - **Haijing Zhiyuan Technology**: A leading Chinese multispectral AI technology company, with revenues of approximately CNY 224.7 million, CNY 117.1 million, and CNY 522.6 million for the fiscal years 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate of about 52.5% [4] - **Haixi New Drug**: A commercial-stage pharmaceutical company with a diverse product portfolio in the fastest-growing therapeutic areas in China. The company focuses on innovative drugs with significant global market potential, including a potential first-in-class oncology drug [5][6] Group 3: Upcoming Listings - **Yinnuo Pharmaceutical-B**: The first in Asia and third globally to advance a novel GLP-1 receptor agonist to the registration approval stage, with an expected IPO fundraising of HKD 683 million at a price of HKD 18.68 per share [9][10] - **Zhonghui Biotechnology-B**: A vaccine company focused on innovative vaccines and traditional vaccines using new technologies, with an expected IPO fundraising of HKD 518 million at a price range of HKD 12.90 to HKD 15.50 per share [9][10]

Core Viewpoint - OpenAI has released GPT-5, generating significant market interest in the AI sector, while domestic AI companies, such as Shenzhen Haiqing Zhiyuan Technology Co., Ltd., are pursuing IPOs in Hong Kong [1] Company Overview - Shenzhen Haiqing Zhiyuan, founded in 2013, specializes in multispectral AI technology and has developed products for detecting both visible and invisible physical information [1][4] - The company has undergone multiple rounds of financing, achieving a post-money valuation of approximately 3.55 billion yuan during its D round in July 2025 [4] Product and Service Breakdown - Haiqing Zhiyuan's offerings include multispectral AI modules, multispectral AI perception terminals, and multispectral AI large model services [9][10] - The revenue contribution from multispectral AI modules decreased from 84.2% in 2022 to 57.3% in Q1 2025, while the large model services contributed 35.2% of revenue in Q1 2025 [10][11] Financial Performance - The company's revenue for the years 2022, 2023, 2024, and Q1 2025 was approximately 225 million yuan, 117 million yuan, 523 million yuan, and 82 million yuan, respectively, with net profits showing significant fluctuations [17][19] - Despite a loss in 2022, the company paid out 5 million yuan in dividends [18] Market Position and Competition - In 2024, Haiqing Zhiyuan held a market share of approximately 3.5% in China's multispectral AI industry, ranking first, and had a 6.6% share in the embedded multispectral AI module sector, ranking third [21] - The multispectral AI market is projected to grow from 20 billion yuan in 2025 to 58.8 billion yuan by 2029, with a compound annual growth rate of 31% [19] Supply Chain and Client Dependency - The company relies on five major suppliers for raw materials, with procurement from these suppliers accounting for a significant portion of total purchases [15] - Haiqing Zhiyuan's revenue from five major clients represented 42.1% to 64.8% of total revenue during the reporting period, indicating a high dependency on a limited client base [15] Research and Development - The company has invested in R&D, with expenditures ranging from approximately 1.98 million yuan to 2.52 million yuan over the reporting periods, representing 4.8% to 9.5% of total revenue [23]